key: cord-0801100-ns1wnubw
authors: Diez, P. Toquero; Fernández, C. Blanco; Cea, B. Vera; Carrascosa, E. Méndez; García, A. Garrido; Candil, O. Donnay; García, A. I. Ballesteros; Sánchez-Torres, J. M.; Rojo, P. Costas; Solís, R. Mondéjar; Hernandez, B.; Martí, M.D.P. López; Bosch, R. Colomer; Laorden, N. Romero
title: 1621P Emotional distress in cancer patients during the first wave of the COVID-19 pandemic in Madrid
date: 2021-09-30
journal: Annals of Oncology
DOI: 10.1016/j.annonc.2021.08.1614
sha: 7077917be9b7eedc29e82ce60bc41165152c93d7
doc_id: 801100
cord_uid: ns1wnubw

Background: The COVID-19 pandemic has emerged as the most important international health problem of the last decades. This study explores the psychopathological implications that Covid-19 has caused on cancer patients during the first wave of the pandemic in Spain. Methods: In this prospective study, we included cancer patients in active treatment from March to June 2020. A 24-question semi-structured questionnaire was designed to measure baseline demographic, clinical and Covid-19 exposure characteristics. Mental health was assessed using the validated Hospital Anxiety and Depression Scale. A descriptive and analytical univariate analysis of the variables studied was performed. Results have been compared with baseline emotional distress rates from historical cohorts in cancer patients. Results: 104 cancer patients were included;a 52.8% of emotional distress, 42.3% of anxiety and 58.6% of depression were detected. 51% of patients expressed higher concern about cancer diagnosis vs COVID-19 infection. Tumor type, stage, type of oncologic treatment or rescheduling of cancer therapy were not related with higher levels of psychological symptomatology. Patients with previous consumption of psychotropic drugs and those who adopted additional infection prevention measures because they considered themselves at risk of having a more aggressive COVID-19 disease had higher levels of emotional distress (p=0.008;p=0.003), anxiety (p=0.026;p=0.004) and depression (p=0.013;p=0.008). Emotional distress was higher in patients whose financial status had worsened (p=0.002). Anxiety rates were higher among patients who often used relaxing therapies (p=0.011) and those who were frequently exposed to media (p=0.05). Depression rates were higher among patients with lower educational level (p=0.032), in those whose economic situation had worsened (p=0.003), and those who relied on Religion or Faith (p=0.029). Conclusions: High rates of emotional distress have been detected during the first wave of the Covid-19 pandemic among cancer patients in active treatment, however, not higher than expected in this population. The cancer disease itself continues to be the main factor of concern for cancer patients, above and beyond the distress generated by Covid-19 pandemic. Legal entity responsible for the study: Hospital Universitario De La Princesa, Medical Oncology Department. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.

Background: The COVID-19 pandemic has dramatically changed how healthcare services are provided. In order to comply with public health recommendations, the multidisciplinary team (MDT) network of the South East Cancer Centre at University Hospital Waterford made a transition to a virtual meeting format. The centre coordinates a network of eight individual cancer MDTs with three satellite hospitals. Following adaptation to virtual format, remote participants now join by videoconference, telephone call, or by phone application.

Methods: A 30-part questionnaire was developed in electronic format and distributed to consultants who comprise the senior membership of the cancer MDTs. The objectives were to investigate experience of the virtual meetings post-implementation, and assess preference regarding the future of the meetings.

Results: Among 36 respondents, surgeons accounted for 38.9%, medical oncologists (22.2%), pathologists (13.9%), radiologists (11.1%), haematologists (5.6%) and radiation oncology, palliative care and physicians for 2.8% each. The most common means of joining the meeting included videoconference (61.1%), physical attendance at MDT room (19.4%), telephone (11.4%) and by phone application (8.3%). 67% experienced difficulties using the technology including issues connecting (67%) and screen-sharing (50%). 78% reported that the virtual format did not affect their attendance at MDT, with 11% reporting increased attendance. 56% thought the case discussion at the virtual MDT was not as in-depth as the conventional MDTs, but a majority (81%) believe that decisions made are not impacted by the virtual format. 71% believe it has negatively impacted on education. Most respondents (40%) preferred the traditional face-to-face format, with 37% preferring a combination of virtual and face-to-face. The majority of consultants determine that virtual MDTs should continue past social distancing guidelines.

The results of this study suggest that virtual MDT meetings can be implemented into routine MDT practice. Although challenges are encountered, transition to a virtual format enables continuation of MDT meetings in uncertain times and may become a lasting legacy of COVID-19.

Legal entity responsible for the study: C.M. Goggin.

Funding: Has not received any funding. Background: As the COVID-19 vaccine rollout commenced in Australia in early 2021, limited evidence was available internationally about the safety and efficacy of the COVID-19 vaccines for people with cancer, particularly because cancer patients were largely excluded from the initial clinical trials. As such, people with cancer had many questions about the COVID-19 vaccines. Australia's Indigenous and culturally and linguistically diverse (CALD) populations experience poorer cancer outcomes and have specific information needs. As the national cancer control agency, Cancer Australia has a leadership role in providing information to support optimal outcomes for people with cancer, including Australia's Indigenous and CALD populations.

Methods: To understand and address the information needs about COVID-19 vaccines for people with cancer, Cancer Australia undertook a scoping review of national and international published literature and guidance, and sought input from key cancer control experts and consumers. In collaboration with Indigenous health and multicultural communications experts, Cancer Australia developed tailored information for Indigenous Australians and CALD populations affected by cancer.

Results: Cancer Australia developed a range of information resources relating to the COVID-19 vaccines and cancer, including Frequently Asked Questions (FAQs), and multimedia promotional collateral including animation and radio advertisements. The FAQs were adapted to provide culturally appropriate messaging for Indigenous Australians with cancer and translated into the ten most spoken languages in Australia. Multi-channel social media communication promoted uptake of the resources to CALD and Indigenous communities, and between March and May 2021, the social media campaign received over 800,000 impressions and the FAQs approximately 20,000 page views.

Conclusions: Throughout the pandemic, Cancer Australia has been responsive to the unique needs of the Australian cancer community. The development and dissemination of tailored information about COVID-19 vaccines for Indigenous and CALD populations is one example of how Cancer Australia aims to improve outcomes for all people with cancer in Australia.

Legal entity responsible for the study: The authors.

Funding: Has not received any funding. Results: 104 cancer patients were included; a 52.8% of emotional distress, 42.3% of anxiety and 58.6% of depression were detected. 51% of patients expressed higher concern about cancer diagnosis vs COVID-19 infection. Tumor type, stage, type of oncologic treatment or rescheduling of cancer therapy were not related with higher levels of psychological symptomatology. Patients with previous consumption of psychotropic drugs and those who adopted additional infection prevention measures because they considered themselves at risk of having a more aggressive COVID-19 disease had higher levels of emotional distress (p¼0.008; p¼0.003), anxiety (p¼0.026; p¼0.004) and depression (p¼0.013; p¼0.008). Emotional distress was higher in patients whose financial status had worsened (p¼0.002). Anxiety rates were higher among patients who often used relaxing therapies (p¼0.011) and those who were frequently exposed to media (p¼0.05). Depression rates were higher among patients with lower educational level (p¼0.032), in those whose economic situation had worsened (p¼0.003), and those who relied on Religion or Faith (p¼0.029).

Background: Phase I CT are a cornerstone in the treatment of cancer patients. Given the future uncertainties due to COVID19 pandemic, one of the concerns is the potential decrease of new phase I CT entering the clinic in subsequent years. Our aim was to evaluate the impact of COVID19 in the Start-up activities of the phase I Unit at Vall dHebron Institute of Oncology (VHIO). Conclusions: Despite COVID19 and an initial decrease of new studies during 2020, the number of new proposals for phase I CT is increasing in 2021. This appears to be equal for biotech and big pharma proposals. Remote PSSVs are an efficient alternative to on-site visits. Digitalization and measures taken are effective to maintain the Clinical trial start up activity in VHIO and will probably remain after the pandemic is over.

With a median duration of 2.3 months (IQR .9-4.2 months), all sites report a temporary lock down with no (12.5%), minimal (12.5%), moderate (50%) and severe (25%) impact on patient care. Examples of this impact include intra-city travel restrictions (25%), intercity travel restrictions (62.5%), and excessive patient travel costs (75%)

Research Grant: Pfizer; Non-Financial Interests, Institutional, Research Grant: AstraZeneca; Non-Financial Interests, Institutional, Research Grant: Varian; Non-Financial Interests, Personal, Member of the Board of Directors: Global Access to Cancer Care Foundation; Non-Financial Interests

1623P Phase I clinical trials (CT) forge on despite

Early Clinical Drug Development Group, Vall d`Hebron Institute of Oncology (VHIO)-Cellex Center

Legal entity responsible for the study: The authors.